Skip to main content

Breast Cancer - Male News

SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations

THURSDAY, Dec. 12, 2024 – For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, imlunestrant leads to significantly...

U.S. Breast Cancer Deaths Keep Declining, Though Disparities Remain

TUESDAY, Oct. 1, 2024 – While women overall are less likely to die of breast cancer now, some alarming disparities remain, a new American Cancer Society (ACS) analysis warns. Death rates for...

American Indian/Alaska Native Breast Cancer Patients Less Likely to Get Reconstruction

MONDAY, July 8, 2024 — After a mastectomy, some women are less likely than others to have breast reconstruction surgery. Rates of the surgery are consistently lower among American Indian and Alaskan n...

FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer

May 24, 2019 -- Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat ...

FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer

April 4, 2019 – Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for Ibrance...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Breast Cancer

Related drug support groups

tamoxifen, Ibrance